Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
holding | KYTX | Series B Preferred Stock | Feb 7, 2024 | Common Stock | 2.81M | By: Northpond Ventures III, LP | F1, F2 |
Id | Content |
---|---|
F1 | All shares of Series B Convertible Preferred Stock, par value $0.00001 per share (the "Series B Preferred Stock"), of Kyverna Therapeutics, Inc. (the "Issuer") will automatically convert on a 4.5511-for-1 basis into shares of the Issuer's common stock, par value $0.00001 per share (the "Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series B Preferred Stock has no expiration date. |
F2 | Northpond Ventures III GP, LLC ("Northpond III LLC") is the general partner of Northpond Ventures III, LP ("Northpond Fund III"), and Michael P. Rubin is the managing member of Northpond III LLC. As a result, each of Northpond III LLC and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund III. Each of Northpond III LLC and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's respective pecuniary interest therein, if any. |